SGMO Quote, Financials, Valuation and Earnings

bluebird bio has a net margin of -309.84% compared to Sangamo Therapeutics's net margin of -573.01%. Sangamo Therapeutics's return on equity of -217.48% beat bluebird bio's return on equity of -245.94%.

Sangamo Therapeutics has a consensus price target of $5.00, signalling upside risk potential of 476.97%. On the other hand bluebird bio has an analysts' consensus of $23.25 which suggests that it could grow by 271.8%. Given that Sangamo Therapeutics has higher upside potential than bluebird bio, analysts believe Sangamo Therapeutics is more attractive than bluebird bio.

Sangamo Therapeutics has a beta of 1.494, which suggesting that the stock is 49.44% more volatile than S&P 500. In comparison bluebird bio has a beta of 0.785, suggesting its less volatile than the S&P 500 by 21.477%.

Sangamo Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. bluebird bio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sangamo Therapeutics pays -- of its earnings as a dividend. bluebird bio pays out -- of its earnings as a dividend.

Sangamo Therapeutics quarterly revenues are $7.6M, which are smaller than bluebird bio quarterly revenues of $10.6M. Sangamo Therapeutics's net income of -$23.4M is higher than bluebird bio's net income of -$60.8M. Notably, Sangamo Therapeutics's price-to-earnings ratio is -- while bluebird bio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sangamo Therapeutics is 3.03x versus 0.64x for bluebird bio. Usually stocks with elevated PS ratios are considered overvalued.

Inovio Pharmaceuticals has a net margin of -309.84% compared to Sangamo Therapeutics's net margin of -16566.39%. Sangamo Therapeutics's return on equity of -217.48% beat Inovio Pharmaceuticals's return on equity of -119.02%.

Sangamo Therapeutics has a consensus price target of $5.00, signalling upside risk potential of 476.97%. On the other hand Inovio Pharmaceuticals has an analysts' consensus of $7.83 which suggests that it could grow by 307.99%. Given that Sangamo Therapeutics has higher upside potential than Inovio Pharmaceuticals, analysts believe Sangamo Therapeutics is more attractive than Inovio Pharmaceuticals.

Sangamo Therapeutics has a beta of 1.494, which suggesting that the stock is 49.44% more volatile than S&P 500. In comparison Inovio Pharmaceuticals has a beta of 0.917, suggesting its less volatile than the S&P 500 by 8.256%.

Sangamo Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Inovio Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sangamo Therapeutics pays -- of its earnings as a dividend. Inovio Pharmaceuticals pays out -- of its earnings as a dividend.

Sangamo Therapeutics quarterly revenues are $7.6M, which are larger than Inovio Pharmaceuticals quarterly revenues of $117K. Sangamo Therapeutics's net income of -$23.4M is lower than Inovio Pharmaceuticals's net income of -$19.4M. Notably, Sangamo Therapeutics's price-to-earnings ratio is -- while Inovio Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sangamo Therapeutics is 3.03x versus -- for Inovio Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of -309.84% compared to Sangamo Therapeutics's net margin of 2.31%. Sangamo Therapeutics's return on equity of -217.48% beat Pfizer's return on equity of 8.91%.

Sangamo Therapeutics has a consensus price target of $5.00, signalling upside risk potential of 476.97%. On the other hand Pfizer has an analysts' consensus of $31.32 which suggests that it could grow by 18.92%. Given that Sangamo Therapeutics has higher upside potential than Pfizer, analysts believe Sangamo Therapeutics is more attractive than Pfizer.

Sangamo Therapeutics has a beta of 1.494, which suggesting that the stock is 49.44% more volatile than S&P 500. In comparison Pfizer has a beta of 0.613, suggesting its less volatile than the S&P 500 by 38.72%.

Sangamo Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.43% to investors and pays a quarterly dividend of $0.43 per share. Sangamo Therapeutics pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

Sangamo Therapeutics quarterly revenues are $7.6M, which are smaller than Pfizer quarterly revenues of $17.8B. Sangamo Therapeutics's net income of -$23.4M is lower than Pfizer's net income of $410M. Notably, Sangamo Therapeutics's price-to-earnings ratio is -- while Pfizer's PE ratio is 18.64x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sangamo Therapeutics is 3.03x versus 2.35x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Protalix BioTherapeutics has a net margin of -309.84% compared to Sangamo Therapeutics's net margin of 35.65%. Sangamo Therapeutics's return on equity of -217.48% beat Protalix BioTherapeutics's return on equity of 8.75%.

Sangamo Therapeutics has a consensus price target of $5.00, signalling upside risk potential of 476.97%. On the other hand Protalix BioTherapeutics has an analysts' consensus of $14.50 which suggests that it could grow by 482.33%. Given that Protalix BioTherapeutics has higher upside potential than Sangamo Therapeutics, analysts believe Protalix BioTherapeutics is more attractive than Sangamo Therapeutics.

Sangamo Therapeutics has a beta of 1.494, which suggesting that the stock is 49.44% more volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of 0.724, suggesting its less volatile than the S&P 500 by 27.611%.

Sangamo Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sangamo Therapeutics pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

Sangamo Therapeutics quarterly revenues are $7.6M, which are smaller than Protalix BioTherapeutics quarterly revenues of $18.2M. Sangamo Therapeutics's net income of -$23.4M is lower than Protalix BioTherapeutics's net income of $6.5M. Notably, Sangamo Therapeutics's price-to-earnings ratio is -- while Protalix BioTherapeutics's PE ratio is 83.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sangamo Therapeutics is 3.03x versus 3.87x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.